The Role of Public Health in the Fight Against Neglected Tropical Diseases

Neglected Tropical Diseases (NTDs) represent one of the most persistent yet solvable global health challenges of our time. This diverse group of parasitic, bacterial, and viral infections thrives in tropical and subtropical conditions, affecting more than 1.7 billion people worldwide. The term "neglected" reflects a historical reality: these diseases have received comparatively little research funding, media attention, or political priority, despite causing immense suffering and economic loss. Populations living in poverty with limited access to clean water, sanitation, and healthcare are disproportionately affected, creating a vicious cycle where disease perpetuates poverty and poverty perpetuates disease. Public health serves as the primary weapon in this fight, providing the frameworks, strategies, and coordination necessary to control, eliminate, and ultimately eradicate these conditions. Through mass drug administration, vector control, health education, robust surveillance systems, and community engagement, public health interventions have already achieved remarkable successes. Yet the path forward requires sustained commitment, innovation, and global solidarity.

The global burden of NTDs is staggering in both human and economic terms. Together these diseases cause an estimated 200,000 deaths annually and contribute to millions of years lived with disability. Beyond direct health impacts, NTDs cost developing economies billions of dollars each year in lost productivity, reduced educational attainment, and increased healthcare expenditures. Children chronically infected with soil-transmitted helminths experience cognitive impairments that limit their future potential. Adults disfigured by lymphatic filariasis or leprosy face stigma that excludes them from community life and economic opportunities. Understanding this multidimensional burden underscores why public health must remain central to the fight against NTDs.

Understanding Neglected Tropical Diseases

The World Health Organization currently recognises 20 diseases and disease groups as NTDs. These include Buruli ulcer, Chagas disease, dengue and chikungunya, dracunculiasis (guinea-worm disease), echinococcosis, foodborne trematodiases, human African trypanosomiasis (sleeping sickness), leishmaniasis, leprosy (Hansen’s disease), lymphatic filariasis (elephantiasis), mycetoma, onchocerciasis (river blindness), rabies, schistosomiasis (snail fever), soil-transmitted helminthiases (intestinal worms), snakebite envenoming, taeniasis/cysticercosis, trachoma, and yaws. Each disease has unique biological mechanisms, transmission patterns, and clinical manifestations, but they share common features: they disproportionately affect poor and marginalised populations, they cause chronic and often disabling conditions, and they are all preventable or treatable with existing interventions.

Soil-transmitted helminths alone infect over 1.5 billion people globally. These intestinal worms impair physical and cognitive development in children, contribute to anaemia in pregnant women, and reduce adult productivity. Schistosomiasis affects more than 200 million people, causing chronic inflammation of the bladder, intestines, liver, and kidneys, with severe cases leading to bladder cancer and kidney failure. Lymphatic filariasis, transmitted by mosquitoes, causes painful and disfiguring swelling of the limbs and genitals, affecting an estimated 120 million people across 72 countries. Trachoma, the leading infectious cause of blindness, has blinded approximately 1.9 million people and threatens the sight of 150 million more. These numbers illustrate the sheer scale of the challenge.

Why Are They Called "Neglected"?

The label reflects a historical imbalance in global health priorities that persists to this day. While HIV/AIDS, tuberculosis, and malaria garnered substantial international funding, research attention, and political commitment, NTDs were largely overlooked for decades. Between 2000 and 2010, NTDs received less than 1% of global health research and development funding relative to their disease burden. This neglect was not accidental. NTDs primarily affect populations with limited political voice and economic power. Pharmaceutical companies had little incentive to develop drugs for diseases affecting people who could not pay for treatment. Research institutions focused on conditions prevalent in wealthy countries. The result was a profound inequity in global health resource allocation.

This neglect perpetuates cycles of poverty. NTDs cause chronic disability, disfigurement, and cognitive impairment in children, reducing educational attainment and lifetime earnings. Adults with chronic NTDs cannot work productively, further impoverishing families and communities. The stigma associated with conditions like leprosy or lymphatic filariasis leads to social exclusion, discrimination, and mental health problems. In many endemic communities, women and girls face additional burdens, as they are often responsible for collecting water, caring for sick family members, and may be more vulnerable to certain infections. Breaking this cycle requires not only medical interventions but also social and economic development.

The Global Burden in Numbers

NTDs are endemic in 149 countries, with the highest burden concentrated in sub-Saharan Africa, Southeast Asia, and Latin America. Together they account for an estimated 26 million years lived with disability annually. The economic impact is equally stark: NTDs cost developing economies an estimated $5-7 billion each year in lost productivity and direct healthcare costs. Countries like Nigeria, the Democratic Republic of the Congo, India, Bangladesh, and Ethiopia carry some of the highest burdens. Within these countries, the poorest and most remote communities are the hardest hit. Understanding this burden in granular detail helps public health officials prioritise resources and target interventions to those who need them most.

Core Public Health Strategies in Combating NTDs

Public health approaches to NTDs are multifaceted, combining preventive interventions with curative treatment and long-term environmental improvements. Five key strategies form the backbone of global efforts, each adapted to local contexts and disease-specific requirements.

Mass Drug Administration (MDA)

MDA is one of the most effective and cost-efficient public health tools against NTDs. The strategy involves distributing single-dose medications to entire at-risk populations, regardless of infection status, at regular intervals. This approach reduces the reservoir of infection in communities, interrupts transmission cycles, and prevents new infections. For lymphatic filariasis, a combination of ivermectin and albendazole is used annually. For onchocerciasis, ivermectin alone is distributed. Praziquantel targets schistosomiasis, azithromycin treats trachoma, and albendazole or mebendazole is used for soil-transmitted helminths.

MDA campaigns often reach tens of millions of people in a single round. In 2022 alone, more than 1.5 billion treatments were distributed for NTDs globally. The scale and logistics are remarkable: drugs must be transported to remote villages, stored under appropriate conditions, and administered by trained community drug distributors who go door-to-door or set up distribution points at schools and health centres. The WHO coordinates these efforts through partnerships with ministries of health, NGOs, and pharmaceutical companies that donate the medications. The success of MDA depends on high coverage rates, sustained political commitment, and community trust.

Vector Control

Many NTDs are transmitted by insects and other arthropods. Mosquitoes transmit dengue, chikungunya, lymphatic filariasis, and Japanese encephalitis. Black flies transmit onchocerciasis. Sandflies transmit leishmaniasis. Triatomine bugs transmit Chagas disease. Public health agencies implement a range of vector control measures: insecticide-treated bed nets, indoor residual spraying, environmental management to reduce breeding sites, biological control using larvivorous fish, and personal protective measures like repellents.

Successful vector control programmes have produced remarkable results. Onchocerciasis has been eliminated from several regions in West Africa through sustained black fly control using insecticide spraying of rivers. Chagas disease transmission has been dramatically reduced in Latin America through indoor residual spraying and housing improvements that eliminate triatomine bug habitats. Dengue control has proven more challenging, but integrated vector management approaches that combine source reduction, larviciding, and public education have shown success in reducing transmission in countries like Singapore and Cuba.

Water, Sanitation, and Hygiene (WASH)

Access to clean water and proper sanitation is fundamental to preventing many NTDs. Latrines reduce soil contamination with helminth eggs, preventing hookworm, ascariasis, and trichuriasis infections. Safe water supplies prevent guinea worm disease and reduce schistosomiasis transmission. Handwashing with soap reduces trachoma transmission by limiting contact with infected eye secretions. The UNICEF WASH programme works alongside disease-specific initiatives to integrate sanitation improvements into NTD control strategies.

In Ethiopia, combined MDA and WASH interventions have drastically reduced trachoma prevalence from 40% to less than 5% in some districts. In Yemen, community-led total sanitation programmes have reduced soil-transmitted helminth infections. The integration of WASH and NTD programmes is a public health priority, recognised in the WHO NTD roadmap as essential for sustainable elimination. However, achieving universal access to water and sanitation remains a distant goal in many endemic regions, requiring massive infrastructure investments and behaviour change at community level.

Health Education and Behaviour Change

Community education is essential for sustaining prevention behaviours over the long term. Health workers teach people to avoid swimming in snail-infested water, wear shoes to prevent hookworm infection, use bed nets consistently, wash hands with soap at critical times, and recognise early signs of disease. School-based health education programmes are particularly effective, as children become agents of change within their families and communities. In many districts, public health campaigns use radio broadcasts, community theatre performances, mobile phone messages, and social media to spread information about NTDs.

Behaviour change is often the most difficult component of NTD control. People may understand the risks but lack the resources or social support to change deeply ingrained habits. Cultural beliefs about disease causation may conflict with biomedical explanations. Stigma associated with NTDs may prevent people from seeking treatment. Effective health education programmes address these barriers through participatory approaches, involving community members in identifying problems and solutions, and using local languages and culturally appropriate metaphors.

Surveillance and Monitoring

Robust surveillance systems form the nervous system of NTD control programmes. They track disease prevalence, identify outbreaks, measure the impact of interventions, and detect emerging drug resistance. Public health authorities use sentinel site surveys, active case finding, passive case reporting, and rapid diagnostic tests to collect data. This information guides decisions about when to stop MDA, whether to switch strategies, or where to intensify efforts. The CDC Global NTD program supports countries in building surveillance capacity, including the use of geographic information systems for mapping disease hotspots and mobile phone applications for real-time data reporting.

One of the greatest challenges in NTD surveillance is the lack of reliable diagnostic tools. Many NTDs are diagnosed based on clinical symptoms, which can be non-specific or appear only in advanced stages. Rapid point-of-care tests exist for some diseases but not others. Laboratory capacity is limited in remote endemic areas. Investment in diagnostic innovation is critical for improving surveillance and enabling more targeted interventions.

Impact of Public Health Initiatives

Public health-driven efforts against NTDs have produced historic achievements that demonstrate the power of coordinated global action. Guinea worm disease, once endemic in 20 countries across Africa and Asia, is now on the verge of eradication. In 1986, there were an estimated 3.5 million cases. In 2023, there were just 14 human cases reported. This success was achieved through community-based surveillance, cash rewards for reporting cases, health education, and provision of safe drinking water. The campaign, led by The Carter Center in partnership with ministries of health, has been one of the most cost-effective public health interventions in history.

Lymphatic filariasis has been eliminated as a public health problem in 18 countries, including Egypt, Sri Lanka, and Thailand. Trachoma has been eliminated in 15 countries. In 2000, an estimated 1.5 billion people required treatment for trachoma; by 2023, that number had fallen to 100 million. Onchocerciasis transmission has been interrupted in Colombia, Ecuador, Guatemala, and Mexico. In India, leprosy was eliminated as a public health problem in 2005, with prevalence dropping from 5.7 million cases in 1983 to fewer than 100,000 today. These successes demonstrate that with adequate resources, political will, and community engagement, NTDs can be conquered.

Country Case Studies

In Nepal, lymphatic filariasis elimination was achieved through eight rounds of MDA combined with vector control and community engagement. The programme reached more than 15 million people at risk, with coverage rates exceeding 80% in most districts. Nepal was validated by WHO as having eliminated lymphatic filariasis as a public health problem in 2022.

In Morocco, onchocerciasis transmission was interrupted after 17 years of annual ivermectin distribution. Morocco became the first country in Africa to eliminate onchocerciasis in 2016. The programme was integrated into the primary healthcare system, with local health workers responsible for drug distribution and surveillance.

Brazil’s integrated approach to Chagas disease included vector control through indoor residual spraying, blood screening to prevent transfusion transmission, housing improvement to eliminate triatomine bug habitats, and health education. This comprehensive strategy reduced Chagas disease incidence by over 80% between 1990 and 2010. Brazil now screens 100% of blood donations for Chagas disease, preventing thousands of new infections each year.

In Vietnam, lymphatic filariasis was eliminated through a combination of MDA and vector control. Vietnam became the first country in Southeast Asia to achieve elimination in 2018, demonstrating that even resource-limited settings can succeed with strong political commitment and community participation.

Challenges Facing NTD Control

Despite remarkable progress, significant obstacles remain on the path to elimination and eradication. Sustaining and expanding gains requires confronting funding gaps, logistical hurdles, and emerging threats with clear-eyed realism.

Funding and Political Will

NTD programmes are heavily dependent on external donors, including the UK Foreign, Commonwealth and Development Office, the Bill & Melinda Gates Foundation, and USAID. However, global health funding has become increasingly competitive, and NTDs still receive a fraction of the resources allocated to HIV/AIDS, tuberculosis, and malaria. The COVID-19 pandemic exacerbated funding shortfalls, as health budgets were redirected and donor attention shifted. Political instability and conflict can derail campaigns entirely, as seen in Yemen, South Sudan, and parts of the Democratic Republic of the Congo, where ongoing violence has halted MDA and surveillance activities.

The economic case for NTD investment is compelling. Every dollar invested in NTD control returns an estimated $25-50 in economic benefits through improved productivity, reduced healthcare costs, and enhanced educational attainment. But these returns accrue over decades, while the costs are immediate. Sustaining political will requires effective advocacy that communicates both the human and economic dividends of continued investment.

Drug Resistance and Treatment Gaps

Resistance to anthelmintic drugs, while not yet widespread, is a growing concern. Overreliance on a limited number of medications increases the risk of resistance development. For schistosomiasis, praziquantel is the only effective drug available. For soil-transmitted helminths, albendazole and mebendazole are used almost exclusively. For onchocerciasis, ivermectin is the primary treatment. The development of drug resistance could be catastrophic, setting back decades of progress.

Research into new drugs and alternative treatment regimens is urgently needed. The Drugs for Neglected Diseases initiative (DNDi) has been at the forefront of this effort, developing new treatments for leishmaniasis, sleeping sickness, and Chagas disease. However, the drug development pipeline remains thin, and the market incentives for pharmaceutical companies to invest in NTD drugs are weak. Public-private partnerships and push incentives like research grants are essential to accelerate drug discovery.

Climate Change and Urbanisation

Climate change is altering the geographic distribution of vector-borne NTDs. Dengue is expanding into temperate regions that were previously too cold for Aedes mosquitoes. Schistosomiasis may spread to higher altitudes in East Africa as temperatures rise. Leishmaniasis is appearing in new areas of South America. Rising temperatures, changing rainfall patterns, and extreme weather events create conditions favourable for disease transmission.

Urbanisation, particularly when unplanned, creates ideal breeding grounds for vectors and increases disease transmission. Crowded housing, poor sanitation, and inadequate water supply in informal settlements facilitate the spread of dengue, chikungunya, and soil-transmitted helminths. Public health must adapt surveillance and response systems to these dynamic conditions, incorporating climate modelling and urban planning into NTD control strategies.

Weak Health Systems

Many endemic countries have fragile health systems characterised by shortages of trained personnel, inadequate supply chains, poor data management, and limited laboratory capacity. NTD programmes have often been implemented as vertical, stand-alone initiatives funded by external donors. While this approach has produced impressive results, it can undermine sustainability by creating parallel systems that do not strengthen the underlying health infrastructure.

Integrating NTD control into primary healthcare is essential for long-term sustainability. This means training community health workers to diagnose and treat NTDs alongside other common conditions, including NTD medicines on essential drug lists, incorporating NTD surveillance into routine health information systems, and financing NTD activities through domestic budgets rather than relying entirely on external donors. The WHO’s 2021-2030 NTD roadmap strongly emphasises cross-cutting approaches that strengthen overall health systems.

Diagnostic Gaps

Accurate diagnosis is fundamental to effective NTD control, yet many NTDs lack reliable, affordable, and easy-to-use diagnostic tools. Microscopy requires trained technicians and laboratory equipment. Clinical diagnosis is often inaccurate. Serological tests may not distinguish between past and current infection. Rapid diagnostic tests exist for some NTDs but are not widely available for others. The lack of point-of-care diagnostics hinders surveillance, makes it difficult to verify elimination, and can lead to over-treatment or under-treatment.

Future Directions: The Path to Elimination and Eradication

The WHO’s 2021-2030 NTD roadmap sets ambitious targets: at least 100 countries will have eliminated at least one NTD by 2030, the number of people requiring treatment will be reduced by 90%, and national health systems will have the capacity to maintain NTD control without external support. Achieving this vision requires strategic shifts and renewed collaboration across sectors.

Integration with Universal Health Coverage (UHC)

Embedding NTD care into routine health services improves access, reduces stigma, and enhances sustainability. Training community health workers to diagnose and treat NTDs alongside other common conditions expands the reach of primary healthcare. Integrating NTD screening into antenatal care, school health programmes, and chronic disease management creates multiple entry points for treatment. Including NTD medicines on essential drug lists ensures consistent availability. Financing NTD activities through national health budgets rather than donor-funded projects reduces vulnerability to funding fluctuations.

Several countries are already moving in this direction. Ghana has integrated NTD screening into its community-based health planning and services programme. Ethiopia has incorporated NTD treatment into its health extension worker package. Rwanda has included NTD indicators in its health management information system. These examples provide models for other endemic countries to follow.

Innovation in Diagnostics, Drugs, and Vaccines

Investment in research and development remains critical for overcoming remaining barriers. Rapid point-of-care diagnostics that can be used by community health workers with minimal training would enable quicker treatment and more effective surveillance. New drugs are needed to combat emerging resistance and shorten treatment courses. Promising vaccines for leishmaniasis, schistosomiasis, and hookworm are in clinical trials, offering the potential for long-term protection.

The WHO Global Observatory on Health R&D tracks progress in these areas and highlights gaps that require attention. The Coalition for Epidemic Preparedness Innovations has expanded its focus to include NTDs. The Global Fund has begun investing in NTD diagnostics and treatments. However, the level of investment remains far below what is needed. Increasing research funding for NTDs is one of the most cost-effective investments in global health.

Strengthening Partnerships and Community Engagement

No single organisation can defeat NTDs alone. The London Declaration on NTDs, launched in 2012, catalysed unprecedented partnerships between endemic countries, donors, pharmaceutical companies, and NGOs. This coalition has mobilised billions of dollars in drug donations and programme support. Continued collaboration through initiatives like the Uniting to Combat NTDs coalition ensures resources are pooled, best practices shared, and momentum maintained.

Community ownership is essential for long-term success. Village health committees, school health programmes, community drug distributors, and peer educators all play vital roles in MDA, surveillance, and behaviour change. Engaging communities in planning, implementation, and monitoring builds trust, addresses local concerns, and ensures interventions are culturally appropriate. In many settings, community engagement has been the difference between success and failure.

Leveraging Digital Health and Data

Digital technologies offer powerful tools for accelerating NTD control. Mobile phone applications enable community health workers to register households, track drug distribution, and report adverse events in real time. Electronic registries improve data quality and enable more accurate targeting of interventions. Geographic information systems map disease hotspots and track vector breeding sites. Machine learning algorithms can predict disease outbreaks based on climate and environmental data.

Expanding digital health literacy among health workers and investing in robust data infrastructure will accelerate progress toward elimination. Several countries are already using digital tools effectively. Nepal uses a mobile application for lymphatic filariasis MDA tracking. Uganda uses GIS for schistosomiasis mapping. Ethiopia uses electronic health records for NTD surveillance. These innovations demonstrate the potential of digital health to transform NTD control.

Sustaining Elimination and Preventing Re-emergence

Achieving elimination is not the end of the story. Maintaining elimination requires ongoing surveillance, rapid response capacity, and continued public investment. Diseases can re-emerge if surveillance weakens, vector control is neglected, or population movements introduce infections from endemic areas. The COVID-19 pandemic demonstrated how fragile health systems can be and how quickly gains can be lost.

Countries that have eliminated NTDs must maintain strong health systems, continue surveillance, and be prepared to respond to outbreaks. The WHO has established processes for verifying elimination of lymphatic filariasis, onchocerciasis, trachoma, and yaws. These processes require countries to demonstrate sustained surveillance and response capacity. The global community must remain vigilant and supportive, providing technical assistance and resources as needed.

Conclusion

Neglected Tropical Diseases remain a persistent threat to the health and livelihoods of billions of people, but public health has proven that progress is possible. Through coordinated strategies including mass drug administration, vector control, improved water and sanitation, health education, and robust surveillance, the burden of NTDs has been dramatically reduced in many regions. Guinea worm disease is on the verge of eradication. Lymphatic filariasis has been eliminated in 18 countries. Trachoma has been eliminated in 15 countries. Leprosy prevalence has fallen by 95% globally.

However, the challenges that remain demand persistent attention and renewed commitment. Funding shortfalls, drug resistance, climate change, weak health systems, and conflict all threaten to reverse the gains that have been made. The path forward requires integrating NTD control into broader health frameworks, fostering innovation in diagnostics and treatments, strengthening global partnerships, and empowering communities to take ownership of their health. The WHO 2021-2030 roadmap provides a clear vision and strategic direction. Achieving this vision will require not only technical solutions but also political will, sustained investment, and a moral commitment to ensuring that no one suffers needlessly from these preventable and treatable conditions.

The fight against NTDs is one of the most cost-effective investments in global health, offering returns that extend far beyond disease reduction. It is a fight for dignity, opportunity, and human potential. With continued dedication and collaboration, the goal of a world free from NTDs is within reach.